E. Corey

Molecular consequences of acute versus chronic CDK12 loss in prostate carcinoma nominates distinct therapeutic strategies

This study shows that acute CDK12 loss in prostate cancer causes HR deficiency via polyadenylation, but chronic loss leads to adaptation, making PARP inhibitors ineffective and suggesting CDK13 targeting as a new therapeutic approach.

BET inhibitors as a therapeutic intervention in gastrointestinal gene signature-positive castration-resistant prostate cancer.

This study identifies BET inhibitors as effective against GI transcriptome-positive CRPC by targeting HNF1A and HNF4G, improving outcomes in preclinical models.

Imaging and quantification of prostate cancer-associated bone by polarization-sensitive optical coherence tomography

This study uses PS-OCT to differentiate bone tissue types in prostate cancer metastases by analyzing collagen organization and quantifying structural features.

Increased chromatin accessibility mediated by nuclear factor I drives transition to androgen receptor splice variant dependence in castration-resistant prostate cancer

This study shows that ARv7 drives AR activity in castration-resistant prostate cancer through increased chromatin accessibility mediated by NFI factors.

Sclerotic prostate cancer bone metastasis: woven bone lesions with a twist.

This study characterizes the bone structure of prostate cancer bone metastases using multiple techniques and identifies four phenotypes, including osteosclerotic lesions with abnormal woven bone-like features.

Unveiling Novel Double-Negative Prostate Cancer Subtypes Through Single-Cell RNA Sequencing Analysis

This study identifies two novel double-negative prostate cancer subtypes using scRNA-seq and develops a web tool for visualization.

Unraveling the Global Proteome and Phosphoproteome of Prostate Cancer Patient-Derived Xenografts

The paper characterizes the proteome and phosphoproteome of prostate cancer patient-derived xenografts to identify differences between neuroendocrine-like and adenocarcinoma subtypes.

A genome-wide CRISPR screen in human prostate cancer cells reveals drivers of macrophage-mediated cell killing and positions AR as a tumor-intrinsic immunomodulator

This study uses a CRISPR screen to identify genes critical for macrophage-mediated killing of prostate cancer cells, revealing AR as an immunomodulator that promotes resistance to macrophage attack.

ABI1 regulates transcriptional activity of Androgen Receptor by novel DNA and AR binding mechanism

This paper identifies ABI1 as an epigenetic regulator of transcriptional homeostasis in AR-driven cancers through novel DNA and AR binding mechanisms.

GD2 and its biosynthetic enzyme GD3 synthase promote tumorigenesis in prostate cancer by regulating cancer stem cell behavior

This study shows GD2 and its biosynthetic enzyme GD3S promote prostate cancer tumorigenesis by maintaining cancer stem cells and EMT markers.

Nucleosome patterns in circulating tumor DNA reveal transcriptional regulation of advanced prostate cancer phenotypes

This paper identifies nucleosome patterns in ctDNA that distinguish advanced prostate cancer phenotypes, achieving high accuracy in classification using a prediction model.

Discovery and characterization of a first-in-field transcription factor BRN2 inhibitor for the treatment of neuroendocrine prostate cancer.

This paper develops and characterizes B18-94, the first BRN2 inhibitor, showing efficacy in reducing NEPC tumor growth with no toxicity.

Tumor-derived biomarkers beyond antigen expression enhance efficacy of CD276/B7H3 antibody-drug conjugate in metastatic prostate cancer

This study identifies biomarkers beyond B7H3 expression that predict response to a B7H3-ADC in metastatic prostate cancer models, improving therapeutic efficacy.

OncoLoop: A network-based precision cancer medicine framework

OncoLoop predicts and validates drug sensitivity in tumors and their models by leveraging perturbational profiles of oncology drugs, showing success in prostate cancer models and patient cohorts.

HOXB13 suppresses de novo lipogenesis through HDAC3-mediated epigenetic reprogramming

This study identifies HOXB13's AR-independent role in suppressing lipogenesis via HDAC3-mediated epigenetic repression, linking its loss to metastatic prostate cancer progression.

Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer

The paper identifies FOXA1 reprogramming in NEPC and shows its role in maintaining NE lineage features through epigenomic profiling.

Subtype Heterogeneity and Epigenetic Convergence in Neuroendocrine Prostate Cancer

This study identifies two distinct subtypes of neuroendocrine prostate cancer based on neuronal transcription factors and highlights their epigenetic convergence and therapeutic implications.

The expression of YAP1 is increased in high-grade prostatic adenocarcinoma but is reduced in neuroendocrine prostate cancer

This study shows YAP1 is increased in high-grade prostate adenocarcinoma but reduced in neuroendocrine prostate cancer, with YAP1 loss activating Wnt/beta-Catenin signaling linked to NEPC development.

Hypoxia-Induced PIM Kinase and Laminin-Activated Integrin α6 Mediate Resistance to PI3K Inhibitors in Bone-Metastatic CRPC

The paper identifies two survival pathways in bone-metastatic CRPC that confer resistance to PI3K inhibitors and shows combined inhibition of integrin α6β1 and PIM kinase is needed to overcome this resistance.

Targeting RET Kinase in Neuroendocrine Prostate Cancer

The paper identifies RET kinase as a targetable driver in neuroendocrine prostate cancer (NEPC) through phosphoproteomics and pharmacological inhibition studies, showing reduced tumor growth in models.